Clinical Trial Update: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating response- and biology-based risk factor-guided therapy in younger patients with non-high risk neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Children's Oncology Group | Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING